

Predicting the Quality of CDRH3 Antibody Loop Structural Models

Lilian M. Denzler and Andrew C.R. Martin

Structural and Molecular Biology, Division of Biosciences,
University College of London,
Gower Street,
London WC1E 6BT, UK

October 6, 2022

Abstract

Therapeutic antibodies have shown an unprecedented pace of development and have brought new hope for the treatment of numerous diseases. Bioinformatics tools for modelling antibody structures have become invaluable for antibody engineering and the development of therapeutic antibodies. The antigen-binding site consists of six hypervariable loops, also known as the Complementary Determining Regions (CDRs), all of which can be modelled with adequate accuracy, except for one. It remains remarkably difficult to model the third CDR loop of the antibody heavy chain. CDR-H3 has far greater length and sequence variability, with such great structural diversity, that modelling it is considerably harder.

Many approaches for antibody modelling, such as our abYmod software, have been developed. Although such efforts have improved prediction accuracy the results for CDR-H3 are still inconsistent and require further improvement. Providing a confidence score for the structure predictions would aid in differentiating well-modelled structures from incorrectly modelled structures, giving the abYmod user a clearer understanding of the generated 3D-model reliability.

We present a 3D-model quality predictor, combining domain knowledge with machine learning techniques to predict the accuracy of CDR-H3 3D-models generated by antibody modelling software such as abYmod. The newly developed predictor scored a Mathews Correlation Coefficient of 0.99, and can thus be described as highly reliable. The predictor is made available at <http://www.bioinf.org.uk/abs/qualiloop/>

1 Introduction

Antibodies are highly specialized proteins of the immune system that are produced in response to a foreign substance, called an antigen. A mature antibody binds a specific antigen with high affinity, while only weakly interacting with other antigens, or not at all. **Lilian: Introduce the use as drugs** This high affinity and high specificity sets it apart from other pharmaceuticals. Furthermore, in contrast with small drug molecules, antibodies can not only bind pockets, but also flat, concave or convex surfaces[1] **Lilian: Surely you can find a better reference! e.g. our one!** Their unique characteristics have enabled researchers to develop efficient antibody drugs for treating cancers, autoimmune disorders, infectious diseases and many more[2]. Their ability to target an immense variety of antigens allows for endless possibilities in application. Four of the top 10 best-selling drugs in 2020 were monoclonal antibodies[3].

In order to design therapeutic antibodies rationally, knowledge of their structure is essential. The acquired structural information can be used to increase binding affinity to a target of interest, predicting both the exact binding site and the antibody stability as well as assessing immunogenicity[4]. As experimental structure determination is costly and time consuming, computational predictions of an antibody’s structure are used to streamline the process.

The variable fragment (Fv) of an antibody contains the six complementarity determining regions (CDRs, also known as hypervariable loops) which form the antigen binding site. All except one of these loops can be clustered into a limited number of ‘canonical structures’[?]. Therefore, modelling these loops with adequate accuracy is commonly achievable[5, 6]. **Lilian: Is the second reference relevant here?** However, the CDR loop 3 of the heavy chain (CDR-H3) has a far greater sequence variability due to the processes of V(D)J recombination and somatic hyper-mutation and its structure has remained unclassifiable[7]. The variety in structure is so great, that its structural diversity is remarkable even compared to other protein loops[8]. It was found that over 75% of CDR-H3 loops do not have a sub-Ångström non-antibody structural neighbour, while 30% of CDR-H3 loops have a completely unique structure compared with under 3% for all non-antibody loops[8].

Apart from being the most structurally diverse, the CDR-H3 loop is also the most important for antigen binding, being located at the centre of the binding site and forming the most contacts with the antigen[9]. It was demonstrated that differences in this loop alone are sufficient to enable otherwise identical antibodies to distinguish between various antigens[10].

According to the Kabat definition, the CDR-H3 loop is made up of the residues 95–105 (using the Kabat[11], Chothia[?] or Martin[?] numbering schemes) in the heavy chain, with a potential insertion site at position 100. The possibility of such an insertion of a varying number of residues leads to a large range of loop lengths, with bovine antibodies being exceptionally long (Figure 1).




Figure 1: Distribution of CDR-H3 loop lengths in mouse (left), human (centre) and cow (right). Mouse and human antibody CDR-H3s have a unimodal, yet almost normal distribution with a range of ~ 4 –28 and 4–38 respectively. The length cut-off for CDR-H3s depicted above is 30 amino acids. Bovine antibodies with significantly longer CDR-H3 loops than depicted here exist, reaching a length of 67 amino acids and above[12]. **Lilian:** Do we need this?

For shorter loops, a higher prediction accuracy can be achieved than for longer CDR-H3 loops. This was also shown by the Antibody Modelling Assessments (AMA), two blind contests that required researchers to build three-dimensional structural models (3D-models) from antibody sequences. The CDR-H3 loop modelling quality achieved at the contests was on average much lower for loops of longer lengths[13, 14].

Several different approaches for generating 3D-models from antibody sequences exist such as RosettaAntibody[15, 16], ABodyBuilder[17], PIGSPRO[18] **Lilian:** Lyra, AbLooper and our own abYmod. One of the most used methods is RosettaAntibody, which implements template selection and *ab initio* CDR-H3 loop modelling using loop fragments and employing specific angle restraints which bias the conformational space towards so-called ‘kinked’ loops[19, 20]. In contrast, ABodyBuilder uses a database search algorithm (FREAD[21]) for CDR loop modelling. abYmod <http://abymod.abysis.org/> utilizes extensive canonical class definitions, V_H/V_L angle prediction and a large database of loop structures (LoopDB) for CDR-H3 modelling. Upon inputting an antibody sequence, abYmod assigns the canonical class using a set of key residues[22] and where an exact match is not possible, a nearest class is identified.

abYmod selects light and heavy chains separately from PDB templates. First these are selected on the basis of the number of matched canonical classes and then on the basis of sequence identity. The V_H/V_L packing angle is currently selected from the parent that has the best sequence identity over both chains, but an improved method is currently in development. Any CDRs where there was no canonical match are then grafted onto the framework. If there is no template of the correct length for CDR-H3, the loop is built using LoopDB, a database of CDR-H3-like loops from all proteins. Finally, Gromacs energy minimization software is used to optimize the 3D-model. This method has proven

very effective and preliminary analysis suggests the method achieves comparable results, or outperforms, other modelling software (see Results).

Using these mentioned modelling methods, framework regions can generally be predicted with great accuracy (with better than 1Å RMSD[14]), as one can often find a very similar structure for the homology modelling process. However, the CDR loops are not as easily predicted due to their great diversity. If the canonical conformation of CDR loops CDR-L1,L2,L3,H1,H2 can be identified, they too can be modelled rather well, often within 1Å C α RMSD, for CDR-H3 loops the **Lilian:** not sure what ‘average’ and ‘usually’ mean here: average is usually above 3Å[13].

ABodyBuilder is a modelling server that provides the user with a confidence score for each region (e.g. CDR-H2) of the antibody 3D-model. The given score is the probability that a specific region (e.g. CDR-H2) will be modelled within a specific RMSD threshold[17]. Thus, it can be used to obtain an expected RMSD value for a given probability (default 75%). For the CDR-H3 this score is calculated as a function of the loop length. The confidence scorer is described as robust, but less accurate in the case of CDR loops due to the lack of data[17]. ABLooper also provides a confidence metric for the CDR-H3 loop 3D-model, which is estimated by the diversity of a set of predicted conformations for the same loop[23]. However, it remains unclear whether a high prediction diversity score points towards loops with multiple conformations or a low quality 3D-model. Furthermore, it remains unclear how well the generated diversity score reflects 3D-model quality[23].

Modelling the CDR-H3 loop is a hurdle for *in silico* development of therapeutic antibodies. Currently, there is no definite, reliable way to determine how accurate a generated structural 3D-model is within the H3 region. Therefore, we have produced a user-friendly predictor of CDR-H3 3D-model quality. The predictor will give the user an RMSD-range in Ångströms, in which the generated 3D-model lies with a high probability. This information can guide the user in the antibody engineering process. The user has the choice to determine whether the 3D-model is to be used as is, or whether the 3D-model should be re-worked.

2 Results

The software was tested on a test-set of antibody structures used in the 2014 and 2011 Antibody Modelling Assessments [13, 14]. As the results depicted in Figure 2 show, abYmod achieves results similar to, or better than, other modelling programs. However, the outliers with very high RMSD values increase abYmod’s RMSD average. The predictor in this work would aim to identify such outlier 3D-models.

The predictive power of any machine learning model (ML-model) is largely dependent on the quality and size of the dataset on which it was trained. As this




Figure 2: RMSD values of the CDR-H3 loop for structures from the Antibody Modelling Assessment I (2011) and AMAII (2014). abYmod outperforms other modelling software in some instances, but also has much lower accuracy in few outlier cases. Left: an abYmod structure for C705 could be generated, yet the RMSD calculation failed **Lilian: Why? I’m sure we can resolve this!**. Right: Ab01 is the rabbit antibody PDB:4MA3, which was excluded in the CDR-H3 modelling stage in AMAII due to difficulties modelling the overall structure previously. Ab01 is shown for the methods, where generated 3D-models were adequate for RMSD calculation. **Lilian: This needs better explanation**

is a non-linear, complex, multi-class classification problem, a substantial amount of data was required. Thus, an extensive, verified dataset of antibody structures called abYbank/AbDb[24], was utilised (1924 non-redundant structures). The α root-mean-square deviation (RMSD) value between the crystal structures and modelled structures was calculated (see Methods) and was used to classify 3D-models.

The full pipeline for creating the final ML-model starts with feature-set calculation using the antibody sequence. The feature set includes attributes linked to sequence, structure, physical characteristics, interactions, etc., within, as well as outside, the loop. The sequence logo (Figure 3) visualizes amino acid occurrence within the loop sequence, elements of which can be extracted as features [25, 26].

After creating the feature dataset, it is pre-processed (cleaning, scaling, encoding, see methods for details). Structures with a resolution worse than 4Å were removed. **Lilian: You already said it was a non-redundant set? Identical whole antibody structures were removed from the dataset, Lilian: I don’t understand this bit!** while instances of different antibodies that matched in loop sequence were not removed. 3D-Models of some of these structures with the same loop sequence differ significantly. The few large RMSD ranges may stem from low resolution. For example, the highest **Lilian: What does ‘highest’ mean?** data-point contains a structure with a resolution of 3.00Å. **Lilian: Explain Residue**




Figure 3: Sequence Logo of the CDR-H3 loop sequence. Data on amino acid occurrence taken from <http://abymod.abysis.org/> Visualized using Seq2Logo.

Lilian: What's the X-axis numbering? IMGT? Can you highlight the CDR residues (95–122) What range of lengths is included?

differences near the loop may also explain the conformational difference. Some of these structures are complexed while others are not, which may also affect the loop structure (manuscript in preparation).

The target data (i.e. RMSD values) are transformed from numerical values to nominal values so that they can be used for classification. In order to define these nominal categories, the total RMSD range must be divided into categories. This is done either by creating uniform classes i.e. 1–2Å, 2–3Å, etc., (the optimal size of which must be determined), or by creating balanced classes. When creating balanced classes, the upper and lower thresholds of a category are chosen in such a way that each class contains an equal number of instances. This approach was chosen to counteract the skewness of the RMSD distribution. However, this was found to affect the final ML-model’s predictive power negatively. Therefore, uniform classes were used.

They are also transformed **Lilian: explain?** into a set of binary values according to a list of RMSD thresholds. This is done so that binary ML-models can be trained, which will predict the probability e.g. that the 3D-model’s RMSD is above 2Å, 2.2Å, 2.4Å, and so on. The number of binary classifiers incorporated into the first layer has a great effect on the final ML-model, the general trend being that the more binary classifiers are used, the better the nominal prediction.

Lilian: Data?

2.1 Feature Encoding and Selection

As some features are in the form of amino acid names, these must be encoded before they can be passed to a ML-model. The encoding strategy often determines how efficiently the ML-model learns and how much information can be extracted. Different strategies were employed to represent **followed by Lilian: ???** BLOSUM62[?] and **NLF Lilian: ???[?]** encoding. The **physiochemical encoding Lilian: explain** strategy was implemented for all ML-models, being the most effective. However, PCA-3 BLOSUM62[?], a dimensionality-reduced BLOSUM62 encoding method achieved comparable results. Feature selection was conducted to improve the ML-model’s learning capacity. A high-dimensional feature dataset bears the risk of introducing excessive noise, facilitating ML-model over-fitting and can be responsible for an overall decrease in ML-model performance and stability. Each additional input feature forces the ML-model to handle a more complex task, which consumes excess computational power and time and provides more variables leading to over-fitting of the ML-model.

Our ML-model was trained on different feature sets selected using manual selection as well as **algorithmic selection strategies Lilian: Which are?**, in order to determine the most effective feature selection method. None of the feature selection methods was a best fit for all ML-models. **Lilian: Explain**

Lilian: So, having read this, I have no idea what feature encoding you actually used, or where to find that information. What worked and what didn’t? Where

can I find a comparison of the performance?

After the data were processed, they were used to train different ML-models. Different types of ML-model were investigated, as the most suited ML-model type has to be determined heuristically. The following list, which includes some of the most commonly used algorithms, was used: logistic regression, linear discriminant analysis, K-nearest neighbours classifier, decision tree classifier, Gaussian NB, random forest classifier, support vector machine, probability-based voting (also known as soft voting) and extreme gradient boosting (XGBoost)[27]. **Lilian:** OK, but this is the Results section, so where are the results of using the different methods?

The best ML-model, and its best hyperparameters, are then determined for each binary RMSD target. The set of binary ML-models outputs a number of predictions that give the likelihood **Lilian:** is it always a likelihood, or a confidence? Or is that the same thing? of the 3D-model having an RMSD above the threshold value of the respective ML-model. These predictions are then added to the feature set, on which a top-layer classifier is then trained (Figure 4). Thus, a quasi-voting-system is incorporated into the final classifier, in which a set of weaker classifiers vote on the ML-model quality.

2.2 Hyperparameter Optimization

In the process of hyperparameter optimization, the configuration of ML-model parameters which results in best performance is selected. This is usually a computationally expensive and manual procedure. In an effort to automate this process, a population was defined for each ML-model type, so hyperparameter optimization could be conducted automatically for each ML-model and seamlessly integrated into the full ML-model creation process. Two different methods for hyperparameter optimization were tested. The first was a hybrid approach of randomized search and grid search; the second used a genetic algorithm for optimization. The genetic algorithm was found to achieve slightly better results and was employed for optimizing all ML-models.

2.3 Machine Learning Model Performance

The overall best final ML-model was composed of several different binary classifiers, **Lilian:** More detail! with an extreme gradient boosting (XGBoost) top-layer nominal classifier. Features were selected using random forest feature selection. **Lilian:** Explain how this works and which features were selected — and how many? A final MCC **Lilian:** Explain how MCC is calculated over 3 classes value of 0.99 could be achieved for an ML-model using the abYmod log file **Lilian:** What parameters are actually used? as input as well as the loop 3D-model file itself. This value slightly dropped to 0.92 if no such log file was given. This is mainly **Lilian:** is there anything else? due to the fact that the




Figure 4: Simplified pipeline for creating the final machine learning model (ML-model) that will predict 3D-model quality by giving its RMSD range.

template sequence abYmod used to generate the 3D-model is unknown in the latter case.

Lilian: I'm not sure this is in the most logical place — isn't this something that was chosen at the start? (At least in terms of telling the story The classifier predicts whether a 3D-model has an RMSD of below 2Å, between 2–4Å, or above 4Å. These cutoff values were selected based on the observation that abYmod generally produces a 3D-model with RMSD below 4Å. Incorrectly modelled structures (Figure 2) may be identified by screening for structures estimated to have an RMSD above 4Å. If a very high-quality 3D-model is needed one should also exclude 3D-models with RMSD above 2Å.

3 Methods

3.1 Computing

All machine learning, feature selection and hyperparameter optimization algorithms were implemented in Python. The Scikit-learn library was used for training ML-models, the Yellowbrick[28] library was utilized for visualization. All code is available at <https://github.com/LilianDenzler/qualiloop>

The code was run under CentOS 7 on an 8-core virtual machine on an Intel Xeon 4208 CPU with 16Gig RAM.

3.2 Data Pre-Processing and Preparation

Handling Null Values and Duplicates: The dataset containing target RMSD values, and the calculated features was screened for null values. Rows that contained any null values were removed from the dataset (11 rows in total).

3.2.1 Duplicate Screening

Using AbDb's redundancy information it was ensured that no antibodies were present in the dataset more than once. The dataset was additionally screened for duplicate instances. **Lilian:** Did you find any? How was this screening done? It's far from trivial

3.2.2 Scaling

Normalization and Standardization **Lilian:** What's the difference? Explain what they are. were tested as scaling methods. Both approaches are greatly influenced by outliers, and such datapoints are ideally removed for optimal scaling. Here we define outliers as datapoints that lie over 1.5 times the interquartile range (IQR) below the first quartile or above the third quartile. The IQR is defined as the range between quartile 1, i.e. the median of the lower half of the data,

and quartile 3, i.e. the median of the upper half of the data. However, across all features there are a total of 632 outlier values and removing such a large number of datapoints is not a viable option. A robust scaler[?] was also used, which uses statistics that are robust to outliers. The median is set to zero and numerical features are scaled to the interquartile range.

3.2.3 BLOSUM 62 encoding

The BLOSUM62 matrix reflects the frequencies of amino acid substitutions within a locally aligned, conserved regions of proteins with at least 62% similarity. Each amino acid is represented by a row (or column) of the BLOSUM62 matrix. Dimensionality reduction techniques were employed: Principal Component Analysis (PCA), Independent Component Analysis (ICA), projection-based methods (t-SNE, Isomap). Three components were used as features. **Lilian:** All three at once? If not then what did you use in the final models?

3.2.4 Physiochemical Feature Encoding

Nanni and Lumini[?] described a new encoding technique for machine learning classifiers. Many **Lilian:** How many? physiochemical properties are calculated and transformed using a non-linear Fisher transform for dimensionality reduction. A vector of length 19 is produced for each amino acid³⁴ **Lilian:** What is this?. Martin and Abhinandan[?] introduced an encoding using four physiochemical features ²⁵ **Lilian:** What is this?: the total number of sidechain atoms; the number of sidechain atoms in the shortest path from the C α to the most distal atom; the Eisenberg consensus hydrophobicity[29]; the charge (using +0.5 for histidine).

3.3 Dataset-splitting

The final ML-model was evaluated using a test set, separated from the training set at the start in a 30/70 split (lock-box principle) ³⁵ **Lilian:** What is this?. The performance of all individual sub-ML-models of the first layer was determined using stratified K-folds cross-validation (K=10) as the dataset is imbalanced, being skewed towards lower RMSD values. The method is different from normal K-folds cross validation as it uses stratified sampling instead of random sampling. **Lilian:** I think it is still random, it's just that it is selected to represent the imbalance properly This ensures each class is represented, as the percentage of samples for each class is preserved. A validation set, usually used for testing during the optimization stage was omitted in favour of stratified K-folds cross-validation (k=10)[30, 31]. **Lilian:** I don't really understand what you mean here. The stratified cross-validation is going to use a test set in each fold — it's

just that this is selected to fairly represent the imbalance in the training data. Normally the validation set is the set that is held back for final testing — which you say you did.

3.4 Machine Learning Model Assessment

ML-Model assessment must be considered at two levels as performance metrics of binary and multi-class classifiers are calculated differently and must thus be considered separately. The Matthews Correlation Coefficient (MCC)[32] **Lilian:** *That's the wrong Matthews!!!* is deemed the most informative, taking the ratios of the four confusion matrix categories into account [39] **Lilian:** *What is this? There are two papers on MCC being the best.* and is thus more reliable than the F1 score and accuracy. It is also **consistent** **Lilian:** *is that the correct word?! for both binary and multi-class problems and therefore well suited for our purpose.* **Lilian:** *How is MCC calculated for multi-class prediction?*

3.5 Feature Calculations

4 Discussion

The results suggest that our classifier can differentiate between well-modelled and less well-modelled CDR-H3 loop structures. An MCC value of 0.99 was achieved, which underlines this ability for accurate discrimination. Different methods for data pre-processing, feature encoding, feature selection and hyperparameter optimization were tested. Feature encoding methods that were very high-dimensional (one-hot-encoding, BLOSUM62, NLF) were found to be unfavourable. Dimensionality reduction methods (Principal Component Analysis (PCA), Independent Component Analysis (ICA), projection-based methods e.g. t-SNE) were used on BLOSUM62 encoded matrices, which lead to significant improvement. However, a physicochemical encoding strategy was most effective. The selection of features incorporated in the training set seemed to be most important for effective learning. A multitude of methods were tested. No one fit-for-all method for the different ML-models could be found. **Lilian:** *I'm not sure what this means.* However, for our top-layer classifier in our final ML-model recursive feature elimination worked best. A set of commonly used machine learning algorithms were tested, and the best ML-models were incorporated into the final ensemble ML-model. A stacked ML-model approach (consisting of 23 binary classifiers and a single top-layer nominal classifier) was shown to outperform single ML-models. An MCC value of 0.99 was achieved for a classifier predicting whether an input 3D-model has an RMSD value below 2Å, 2Å–4Å or above 4Å.

We are now looking at incorporating the predictor into the antibody modelling process in the selection of high quality CDR-H3 models given a set of potential

Feature Name	Description	Method of Calculation
Sequence	Amino acid sequence of the CDR-H3 loop.	Sequence is given in one-letter amino acid codes.
Length	Number of residues in the CDRH3-loop, which is located at residues H95-H102.	The number of residues are counted.
Sequence identity	Sequence identity of selected template (SeqA) with input loop sequence (SeqB) is determined after sequence alignment. Calculated by abYmod during modelling.	$\text{Identity}(\text{SeqA}, \text{SeqB}) = 100\% \frac{\text{identical residues}}{\text{length}(\text{alignment})}$
Sequence similarity	Sequence similarity of selected template (SeqA) with input loop sequence (SeqB) is determined after sequence alignment. Calculated by abYmod during modelling. Similar residues are residues that have undergone conservative substitution.	$\text{Simialrity}(\text{SeqA}, \text{SeqB}) = 100\% \frac{\text{identical residues} + \text{similar residues}}{\text{length}(\text{alignment})}$
Loop protrusion	Distance of loop residue further away from the loop base.	Geometrical calculations, see fig. 8
Protruding residue	The amino acid code of the most protruding loop residue	Using the previously determined point furthest away from the loop base, the residue at this coordinate is determined and given as a one-letter amino acid code.
Charge	Total charge of the loop	Sum of charges of all residues in loop
Charge difference	Difference in total charge compared to template sequence	Difference between the two summed charges
Hydrophobicity	Mean of hydrophobicity values of loop	Based Eisenberg consensus values ³⁰
Hydrophobicity difference	Sum of absolute differences between loop sequence and template loop	Based Eisenberg consensus values ³⁰
Accessibility	Total and average accessibility for the loop.	Lee-Richards method ³¹ implemented using the pbsolv method from the BiopTools library ³²
Side-chain Accessibility	Total and average side-chain accessibility for the loop.	Lee-Richards method ³¹ implemented using the pbsolv method from the BiopTools library ³²
Relative Accessibility	Total and average relative accessibility for the loop.	Lee-Richards method ³¹ implemented using the pbsolv method from the BiopTools library ³²
Relative side-chain accessibility	Total and average relative side-chain accessibility for the loop.	Lee-Richards method ³¹ implemented using the pbsolv method from the BiopTools library ³²
Happiness	Happiness score, taking accessibility and hydrophobicity into account. If a residue is 'happy' it will not be a buried hydrophilic or a surface hydrophobic residue.	<p>Hydrophobicity values (see above) are normalized to a range of -1 to +1. Mean accessibility values are calculated as above. If Hydrophobicity of loop is <0:</p> $\text{Happiness} = 1 + (\text{Hydrophobicity} * (1 - \text{Accessibility}))$ <p>Otherwise:</p> $\text{Happiness} = 1 - (\text{Hydrophobicity} * \text{Accessibility})$
Nr. Of contacts	Nr of contacts made by the residue of the loop within a range of 3.5Å. Includes mainchain as well as sidechain atoms. Contacts made with residue within and outside of the loop are counted separately and as total. The ratio of inside vs outside is also calculated.	Modified version of the rangecontacts method in the BiopTools library ³² .
Energy	Potential energy of the model.	Calculated by Gromacs ³³ during energy minimization step in abYmod modelling.
Lowest BLOSUM 62 Scoring Residue Pair	Each possible residue pair in the CDR-H3 loop is scored by their BLOSUM 62 score. The lowest scoring pair's BLOSUM62 value will be combined with their residue separation to form the metric.	<p>With separation being the number of residues between the worst residue pair, and the worst score being the lowest BLOSUM62 score achieved by a residue pair, the metric is calculated as follows:</p> $\text{WorstBLOSUM} = -\log_2(\text{separation}) * \text{worst score}$

Figure 5: A summary of how different feature values were calculated. **Lilian:** It's a table! Why import it?




Figure 6: Diagram **Lilian:** Needs a much simpler cartoon diagram — it’s difficult to see anything from this! visualizing the process underlying the protrusion calculation. First, the base residues (i.e. H95 and H102, shown as red spheres) of the CDR-H3 (shown in red) are identified. Then, a line is drawn between the two $C\alpha$ atoms of these residues (yellow dashed line). The distance of the $C\alpha$ -atom of each residue in the CDR-H3 loop to this line is calculated. The residue which has the greatest distance to the line (shown as green sphere) is output as one-letter amino acid code and used as feature. The distance in Å (depicted as yellow arrow) is used as the ‘protrusion’ feature. **Lilian:** It’s unclear whether you use both distance and amino acid, or just one of these.

decoys.

In a future research project residue patterns in correlation with RMSD may be analyzed. Possibly, one might identify certain sequence patterns that make accurate modelling with abYmod more difficult. Furthermore, separate classifiers according to loop length can be built. Given that loop length is the most important determinant of 3D-model quality, this approach may yield some insight into the challenges of modelling shorter *vs.* longer loops. One could also conduct an analysis of the predictor’s behaviour when abYmod is forced to use LoopDB-based modelling. This might shed light on whether the ML-model presented in this paper is biased towards abYmod’s used source of template structures. It would also give an indication of how well the predictor would work in combination with other modelling software. **Lilian:** We don’t really need this, but can we see any trends from the feature selection?

Lilian: We need a concluding paragraph relating back to the introduction and what this contributes to improvements in using antibody models.

References

- [1] Jr Charles A Janeway, Paul Travers, Mark Walport, and Mark J Shlomchik. The interaction of the antibody molecule with specific antigen. In *Janeway’s*

Immunobiology. Garland Science, 2001.

- [2] Ruei Min Lu, Yu Chyi Hwang, I. Ju Liu, Chi Chiu Lee, Han Zen Tsai, Hsin Jung Li, and Han Chung Wu. Development of therapeutic antibodies for the treatment of diseases. *Journal of Biomedical Science*, 27:1–30, 1 2020.
- [3] Lisa Urquhart. Top companies and drugs by sales in 2020. *Nature Reviews Drug Discovery*, 4 2021.
- [4] K. R. Abhinandan and Andrew C.R. Martin. Analyzing the ‘degree of humanness’ of antibody sequences. *Journal of Molecular Biology*, 369:852–862, 6 2007.
- [5] Benjamin North, Andreas Lehmann, and Roland L. Dunbrack. A new clustering of antibody CDR loop conformations. *Journal of Molecular Biology*, 406:228–256, 2 2011.
- [6] Brian D. Weitzner, Roland L. Dunbrack, and Jeffrey J. Gray. The origin of CDR H3 structural diversity. *Structure*, 23:302–311, 2 2015.
- [7] Jessica A. Finn, Julia Koehler Leman, Jordan R. Willis, Alberto Cisneros, James E. Crowe, and Jens Meiler. Improving loop modeling of the antibody complementarity-determining region 3 using knowledge-based restraints. *PLOS ONE*, 11:e0154811, 5 2016.
- [8] Cristian Regep, Guy Georges, Jiye Shi, Bojana Popovic, and Charlotte M. Deane. The H3 loop of antibodies shows unique structural characteristics. *Proteins: Structure, Function and Bioinformatics*, 85:1311–1318, 7 2017.
- [9] Robert M. MacCallum, Andrew C.R. Martin, and Janet M. Thornton. Antibody-antigen interactions: Contact analysis and binding site topography. *Journal of Molecular Biology*, 262:732–745, 10 1996.
- [10] John L. Xu and Mark M. Davis. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. *Immunity*, 13:37–45, 2000.
- [11] Elvin A. Kabat, Tai Te Wu, Harold M. Perry, Kay S. Gottesman, and C. Foeller. *Sequences of Proteins of Immunological Interest*. U.S. Department of Health and Human Services, Fifth edition, 1991.
- [12] Tzu Tsung Wong. Performance evaluation of classification algorithms by k-fold and leave-one-out cross validation. *Pattern Recognition*, 48:2839–2846, 9 2015.
- [13] Juan C. Almagro, Mary Pat Beavers, Francisco Hernandez-Guzman, Johannes Maier, Jodi Shaulsky, Kenneth Butenhof, Paul Labute, Nels Thorsteinson, Kenneth Kelly, Alexey Teplyakov, Jinqun Luo, Raymond

- Sweet, and Gary L. Gilliland. Antibody modeling assessment. *Proteins: Structure, Function and Bioinformatics*, 79:3050–3066, 11 2011.
- [14] Juan C. Almagro, Alexey Teplyakov, Jinqun Luo, Raymond W. Sweet, Sreekumar Kodangattil, Francisco Hernandez-Guzman, and Gary L. Gilliland. Second antibody modeling assessment (AMA-II). *Proteins: Structure, Function and Bioinformatics*, 82:1553–1562, 2014.
 - [15] Aroop Sircar, Eric T. Kim, and Jeffrey J. Gray. RosettaAntibody: Antibody variable region homology modeling server. *Nucleic Acids Research*, 37:W474–W479, 2009.
 - [16] Arvind Sivasubramanian, Aroop Sircar, Sidhartha Chaudhury, and Jeffrey J. Gray. Toward high-resolution homology modeling of antibody Fv regions and application to antibody-antigen docking. *Proteins: Structure, Function, and Bioinformatics*, 74:497–514, 2 2009.
 - [17] Jinwoo Leem, James Dunbar, Guy Georges, Jiye Shi, and Charlotte M. Deane. ABodyBuilder: Automated antibody structure prediction with data-driven accuracy estimation. *mAbs*, 8:1259–1268, 10 2016.
 - [18] Rosalba Lepore, Pier P. Olimpieri, Mario A. Messih, and Anna Tramontano. PIGSPro: Prediction of immunoglobulin structures v2. *Nucleic Acids Research*, 45:W17–W23, 7 2017.
 - [19] Clara T. Schoeder, Samuel Schmitz, Jared Adolf-Bryfogle, Alexander M. Sevy, Jessica A. Finn, Marion F. Sauer, Nina G. Bozhanova, Benjamin K. Mueller, Amandeep K. Sangha, Jaume Bonet, Jonathan H. Sheehan, Georg Kuenze, Brennica Marlow, Shannon T. Smith, Hope Woods, Brian J. Bender, Cristina E. Martina, Diego Del Alamo, Pranav Kodali, Alican Gulsevin, William R. Schief, Bruno E. Correia, James E. Crowe, Jens Meiler, and Rocco Moretti. Modeling immunity with Rosetta: Methods for antibody and antigen design. *Biochemistry*, 60:825–846, 3 2021.
 - [20] Brian D. Weitzner and Jeffrey J. Gray. Accurate structure prediction of CDR H3 loops enabled by a novel structure-based C-terminal constraint. *The Journal of Immunology*, 198:505–515, 1 2017.
 - [21] Yoonjoo Choi and Charlotte M. Deane. FREAD revisited: Accurate loop structure prediction using a database search algorithm. *Proteins: Structure, Function, and Bioinformatics*, 78:1431–1440, 5 2010.
 - [22] Andrew C.R. Martin and Janet M. Thornton. Structural families in loops of homologous proteins: Automatic classification, modelling and application to antibodies. *Journal of Molecular Biology*, 263:800–815, 11 1996.

- [23] Brennan Abanades, Guy Georges, Alexander Bujotzek, and Charlotte M. Deane. ABlooper: fast accurate antibody CDR loop structure prediction with accuracy estimation. *Bioinformatics*, 38:1877–1880, 3 2022.
- [24] Saba Ferdous and Andrew C R Martin. AbDb: antibody structure database — a database of pdb-derived antibody structures. *Database*, 2018, 1 2018.
- [25] Martin Christen Frolund Thomsen and Morten Nielsen. Seq2Logo: A method for construction and visualization of amino acid binding motifs and sequence profiles including sequence weighting, pseudo counts and two-sided representation of amino acid enrichment and depletion. *Nucleic Acids Research*, 40, 7 2012.
- [26] Mark C. Shaner, Ian M. Blair, and Thomas D. Schneider. Sequence logos: A powerful, yet simple, tool. *Proceedings of the Annual Hawaii International Conference on System Sciences*, 1:813–821, 1993.
- [27] Tianqi Chen and Carlos Guestrin. XGBoost: a scalable tree boosting system. In *Proceedings of the ACM SIGKDD International Conference on Knowledge Discovery and Data Mining*, volume 13-17-August-2016, pages 785–794. Association for Computing Machinery, 8 2016.
- [28] Benjamin Bengfort, Rebecca Bilbro, Paul Johnson, Philippe Billet, Prema Roman, Patrick Deziel, Kristen McIntyre, Larry Gray, Anthony Ojeda, Edwin Schmierer, Adam Morris, and Molly Morrison. Yellowbrick v1.3, 2 2021.
- [29] David Eisenberg, Robert M. Weiss, Thomas C. Terwilliger, and William Wilcox. Hydrophobic moments and protein structure. *Faraday Symposia of the Chemical Society*, 17:109–120, 1 1982.
- [30] Damjan Krstajic, Ljubomir J. Buturovic, David E. Leahy, and Simon Thomas. Cross-validation pitfalls when selecting and assessing regression and classification models. *Journal of Cheminformatics*, 6:10, 3 2014.
- [31] Ron Kohavi. A study of cross-validation and bootstrap for accuracy estimation and model selection, 1995.
- [32] B. W. Matthews. Comparison of the predicted and observed secondary structure of T4 phage lysozyme. *BBA - Protein Structure*, 405:442–451, 10 1975.